PrescQIPP e learning

Lipid modification - High quality e-learning courses from PrescQIPP

This course is designed for medicines optimisation teams, GPs, practice nurses, practice pharmacists, PCN pharmacists, care home pharmacists and pharmacy technicians.
The course covers cardiovascular statistics and risk factors, the recommendations in NICE CG181, the drugs used to treat hypercholesterolaemia; statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, inclisiran and icosapent ethyl. It considers the national lipid management pathway and how the drugs fit into the treatment pathway.

Course content

- This e-learning course has ten modules, three case studies and a final exam with a 70% pass mark
- Once the course is passed a certificate of completion will be issued

MODULE 1	**Introduction** • The scale of cardiovascular disease (CVD) in the UK • Risk factors for CVD and how some of these may be modified • The difference between primary and secondary prevention of CVD
MODULE 2	**Cholesterol and hypercholesterolaemia** • The different types of cholesterol and their bearing on CVD risk • Cholesterol targets in national and international guidelines • Different types of hypercholesterolaemia
MODULE 3	**NICE Clinical Guideline 181** • How to use QRISK to estimate a person's risk of CVD • Lifestyle modifications that may improve cholesterol levels • When statins should be offered for prevention of CVD • How best to communicate risk and treatment options
MODULE 4	**Statins** • Strong evidence base for statins in reducing cardiovascular events • The contraindications, cautions, interactions and monitoring requirements • Adverse reactions to statins, the potential for statin intolerance and how to manage it
MODULE 5	**Ezetimibe** • NICE TA385 on the use of ezetimibe • Evidence base for ezetimibe from the IMPROVE-IT and Treat Stroke to Target trials • The place of ezetimibe in the treatment of hypercholesterolaemia

PrescQIPP e-learning

MODULE 6	**PCSK9 inhibitors** • NICE eligibility criteria for PCSK9 inhibitors • The evidence base for PCSK9 inhibitors • When to refer appropriate patients for initiation of PCSK9 inhibitors
MODULE 7	**Bempedoic acid** • NICE TA694 on the use of bempedoic acid with ezetimibe • The evidence base for bempedoic acid with ezetimibe • The place of bempedoic acid with ezetimibe in the treatment of hypercholesterolaemia
MODULE 8	**Inclisiran** • NICE TA733 on the use of inclisiran • The evidence base for inclisiran • The place of inclisiran in the treatment of hypercholesterolaemia
MODULE 9	**Icosapent ethyl** • Recommendations in NICE TA805 on the use of icosapent ethyl • Clinical evidence for icosapent ethyl from the REDUCE-IT trial • Adverse effects associated with icosapent ethyl and the consequent monitoring that may be required
MODULE 10	**National guidance for lipid management** • National guidance for lipid management for primary and secondary prevention of CVD • Shared decision making in relation to lipid lowering medicines • Local lipid management pathways

How to buy and access the course

- The course costs £14.99 (+VAT)
- Purchase at the PrescQIPP e-learning store

Access the whole range of PrescQIPP e-learning courses.

PrescQIPP is a not-for-profit company that provides robust, evidence-based resources to NHS and social care organisations to help improve medicines-related care for patients.

All e-learning courses are CPD accredited.

If you have any questions about the courses, please contact elearning@prescqipp.info.